A Phase 3 interventional study of V503 and GARDASIL in Papilloma Viral Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 7 sites in 3 countries. Open to participants aged 16 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-01.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 17th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 5th registered.
580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Indiana University · Sites in Kenya
Ages 9–49 · Women only · Healthy volunteers
Western Institute for Veterans Research · Sites in United States
Ages 18+
Talia Sainz Costa · Sites in Spain
Ages 9–18 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 16 Years to 26 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 17 · Phase 4 10
First in 2009; this study’s year is marked. 2 started in 2014.
This study's enrollment of 500 is above the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.
Median enrollment 700 across the 31 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
38 studies in Papillomavirus Infections by Merck & Co., Inc: 1 open now, 7 under way, 6 of them phase 3. Of 30 finished, 26 (87%) have results posted.
Among the 38 studies in Papillomavirus Infections by Merck & Co., Inc, this one is the 22nd largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2014, is one of 26 in phase 3, and was the 26th registered.
Merck & Co., Inc’s Papillomavirus Infections studies by the year they started, since 2000.
3 of the studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04199689Phase 3Merck Sharp & Dohme LLCEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 2027-01-15 |
| NCT04206813Boston Medical CenterAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | 2026-12 |
| NCT07303751Institut d'Investigació Biomèdica de BellvitgeStudy Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV | 2027-02-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, from their registry updates:
Among Merck & Co., Inc’s 38 in Papillomavirus Infections:
This tab as a report to print or save as PDF → With an account.
Primary objective
To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
Secondary objectives
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
Biological: V503
Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
Biological: GARDASIL
9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
Also known as: 9vHPV vaccine
Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
Also known as: qHPV vaccine
Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18
Serum antibodies to HPV types 6, 11, 16, and 18 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.
Time frame: 4 weeks postdose 3 (Month 7)
GMTs to HPV Types 31/33/45/52/58
Serum antibodies to HPV types 31, 33, 45, 52, and 58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.
Time frame: 4 weeks postdose 3 (Month 7)
Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58
Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Type 33: ≥8; HPV Type 45: ≥8; HPV Type 52: ≥8; HPV Type 58: ≥8.
Time frame: 4 weeks postdose 3 (Month 7)
Percentage of Participants With One or More Adverse Events
The percentage of participants with one or more adverse events was assessed.
Time frame: Up to 15 days after any vaccination
Percentage of Participants With Study Discontinuation Due to an Adverse Event
The percentage of participants discontinued from the study due to an adverse event was assessed.
Time frame: Up to Month 7
Percentage of Participants With One or More Injection-site Adverse Reactions
The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.
Time frame: Up to 5 days after any vaccination
Percentage of Participants With Maximum Temperature ≥37.8 °C
The percentage of participants with a maximum temperature ≥37.8 °C was assessed.
Time frame: Up to 5 days after any vaccination
Percentage of Participants With One or More Systemic Adverse Events
The percentage of participants with one or more systemic adverse events was assessed.
Time frame: Up to 15 days after any vaccination
Percentage of Participants With One or More Serious Adverse Events
The percentage of participants with one or more serious adverse events was assessed.
Time frame: Up to 15 days after any vaccination
A total of 502 participants were screened and 500 were randomized
| Milestone | V503 | GARDASIL |
|---|---|---|
| Started | 249 | 251 |
| Vaccinated | 249 | 251 |
| Completed | 246 | 243 |
| Not completed | 3 | 8 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 6 |
Serum antibodies to HPV types 6, 11, 16, and 18 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.
| milli Merck U/mL | V503 | GARDASIL |
|---|---|---|
| HPV Type 6 | 758.3 (665.9 to 863.4) | 618.4 (554.0 to 690.3) |
| HPV Type 11 | 681.7 (608.9 to 763.4) | 769.1 (683.5 to 865.3) |
| HPV Type 16 | 3924.1 (3513.8 to 4382.3) | 3787.9 (3378.4 to 4247.0) |
| HPV Type 18 | 884.3 (766.4 to 1020.4) | 790.9 (683.0 to 915.7) |
Serum antibodies to HPV types 31, 33, 45, 52, and 58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.
| milli Merck U/mL | V503 | GARDASIL |
|---|---|---|
| HPV Type 31 | 794.4 (694.2 to 909.2) | 14.8 (12.5 to 17.5) |
| HPV Type 33 | 460.5 (410.6 to 516.4) | 3.4 (3.1 to 3.7) |
| HPV Type 45 | 262.9 (226.2 to 305.5) | 2.5 (2.3 to 2.8) |
| HPV Type 52 | 430.7 (377.8 to 491.0) | 1.9 (1.8 to 2.1) |
| HPV Type 58 | 691.0 (614.9 to 776.5) | 5.7 (5.0 to 6.5) |
Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Type 33: ≥8; HPV Type 45: ≥8; HPV Type 52: ≥8; HPV Type 58: ≥8.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| HPV Type 6 | 98.2 (95.6 to 99.5) | 98.7 (96.2 to 99.7) |
| HPV Type 11 | 100 (98.4 to 100) | 100 (98.4 to 100) |
| HPV Type 16 | 100 (98.4 to 100) | 100 (98.5 to 100) |
| HPV Type 18 | 99.6 (97.6 to 100) | 99.6 (97.7 to 100) |
| HPV Type 31 | 100 (98.4 to 100) | 61.6 (55.1 to 67.8) |
| HPV Type 33 | 100 (98.4 to 100) | 16.9 (12.4 to 22.4) |
| HPV Type 45 | 100 (98.4 to 100) | 9.3 (5.9 to 13.8) |
| HPV Type 52 | 100 (98.4 to 100) | 2.5 (0.9 to 5.5) |
| HPV Type 58 | 100 (98.4 to 100) | 36.1 (29.9 to 42.6) |
The percentage of participants with one or more adverse events was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With One or More Adverse Events | 82.3 (76.9 to 86.8) | 81.9 (76.5 to 86.4) |
The percentage of participants discontinued from the study due to an adverse event was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With Study Discontinuation Due to an Adverse Event | 0 (0 to 1.5) | 0 (0 to 1.5) |
The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With One or More Injection-site Adverse Reactions | 79.0 (73.4 to 83.9) | 72.2 (66.2 to 77.7) |
The percentage of participants with a maximum temperature ≥37.8 °C was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With Maximum Temperature ≥37.8 °C | 2.8 | 2.4 |
The percentage of participants with one or more systemic adverse events was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With One or More Systemic Adverse Events | 40.7 (34.6 to 47.1) | 40.3 (34.2 to 46.7) |
The percentage of participants with one or more serious adverse events was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With One or More Serious Adverse Events | 0.0 (0.0 to 1.5) | 0.0 (0.0 to 1.5) |
Collected over All adverse events: up to 15 days after each vaccination; serious adverse events: up to Month 7. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V503 | — | 0/248 (0%) | 196/248 (79%) |
| GARDASIL | — | 6/248 (2.4%) | 189/248 (76.2%) |
| Event | V503 | GARDASIL |
|---|---|---|
| Cytomegalovirus infectionInfections and infestations | 0/248 | 1/248 |
| ConcussionInjury, poisoning and procedural complications | 0/248 | 1/248 |
| Foot fractureInjury, poisoning and procedural complications | 0/248 | 1/248 |
| Joint dislocationInjury, poisoning and procedural complications | 0/248 | 1/248 |
| Ligament injuryInjury, poisoning and procedural complications | 0/248 | 1/248 |
| Ligament ruptureInjury, poisoning and procedural complications | 0/248 | 1/248 |
| Event | V503 | GARDASIL |
|---|---|---|
| Injection-site painGeneral disorders | 193/248 | 174/248 |
| Injection-site erythemaGeneral disorders | 38/248 | 43/248 |
| HeadacheNervous system disorders | 29/248 | 37/248 |
| Injection-site swellingGeneral disorders | 36/248 | 23/248 |
| NasopharyngitisInfections and infestations | 11/248 | 14/248 |
Randomized participants
| Age, Continuous(Years) | V503 | GARDASIL | Total |
|---|---|---|---|
| Mean | 20.8 ± 2.7 | 21.3 ± 3.0 | 21.0 ± 2.8 |
| Age, Customized(Participants) | V503 | GARDASIL | Total |
|---|---|---|---|
| <18 years old | 37 | 38 | 75 |
| >=18 years old | 212 | 213 | 425 |
| Sex: Female, Male(Participants) | V503 | GARDASIL | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 249 | 251 | 500 |
The record gives a start of Mar 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent